Martine B.W. Prinsen

Author

Center for Translational Molecular Medicine

Also Known As

Alraiisi, Fatma, M. Prinsen, M.B.W. Prinsen, Martine B. Prinsen, Martine B. W. Prinsen, Martine B.W. Prinsen, Martine Prinsen

104

Publications

632

Citations

H-Index

Concepts

All Affiliations

Center for Translational Molecular Medicine University Medical Center Utrecht Utrecht University

About

Martine B.W. Prinsen is an author at Center for Translational Molecular Medicine specializing in medicine, drug discovery, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	394
2	Cell Biology	3	3	184
3	Health Sciences	1	1	24
4	Natural Sciences	1	1	49
5	Cellular Physiology	1	1	39

Martine B.W. Prinsen

Publications

622

Citations

H-Index

Page 1

	Year	Citations
Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model Ana Maia, J. de Man, Ute Boon, Annals of Oncology Breast OncologyMedicineImmune Checkpoint InhibitorBreast CancerCancer Biology	2015	121
Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use Joost C.M. Uitdehaag, Jeroen A.D.M. de Roos, Antoon M. van Doornmalen, PLoS ONE Kinase Inhibitor DrugsTumor BiologyClinical UseBiochemical SelectivitiesOncology	2014	99
Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells Inge The, Suzan Ruijtenberg, Benjamin Pierre Bouchet, Nature Communications	2015	83
TTK Inhibitors as a Targeted Therapy for <i>CTNNB1</i> ( <b>β</b> -catenin) Mutant Cancers Guido J.R. Zaman, Jeroen A.D.M. de Roos, Marion A.A. Libouban, Molecular Cancer Therapeutics	2017	63
Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity Joost C.M. Uitdehaag, Jos de Man, Nicole Willemsen‐Seegers, Journal of Molecular Biology Drug TargetSignal TransductionSignaling PathwayMedicineReceptor Tyrosine Kinase	2017	62
Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance Nicole Willemsen‐Seegers, Joost C.M. Uitdehaag, Martine B.W. Prinsen, Journal of Molecular Biology Molecular DockingMedicinal ChemistryDrug TargetMedicineNatural Sciences	2016	49
Caenorhabditis elegans Cyclin D/CDK4 and Cyclin E/CDK2 Induce Distinct Cell Cycle Re-Entry Programs in Differentiated Muscle Cells Jerome Korzelius, Inge The, Suzan Ruijtenberg, PLoS Genetics Transcriptional RegulationSignal TransductionDevelopmental BiologyCell DivisionCell Cycle Exit	2011	39
Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017 Joost C.M. Uitdehaag, Jeffrey J. Kooijman, Jeroen A.D.M. de Roos, Molecular Cancer Therapeutics	2018	27
Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs Joost C.M. Uitdehaag, Jeroen A.D.M. de Roos, Antoon M. van Doornmalen, PLoS ONE Drug TargetMyc-driven Cell GrowthSelective TargetingCell ProliferationTumor Biology	2015	24
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020 Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus, Frontiers in Oncology	2022	20

Page 1